Allgemeine Informationen
  • Krankheitskategorie Andere (BASEC)
  • Rekrutierungsstatus Rekrutierung läuft (BASEC/ICTRP)
  • Studienstandort
    Genf
    (BASEC)
  • Studienverantwortliche RANAIVOSON Hanta clinical.study@spinevision.com (BASEC)
  • Datenquelle(n) BASEC: Import vom 23.05.2025 ICTRP: N/A
  • Letzte Aktualisierung 23.05.2025 10:56
HumRes63394 | SNCTP000005704 | BASEC2023-D0072

Safety and performance of the Hexanium TLIF system in the treatment of skeletally mature patients with degenerative disc disease – HEXANIUM TLIF Study

  • Krankheitskategorie Andere (BASEC)
  • Rekrutierungsstatus Rekrutierung läuft (BASEC/ICTRP)
  • Studienstandort
    Genf
    (BASEC)
  • Studienverantwortliche RANAIVOSON Hanta clinical.study@spinevision.com (BASEC)
  • Datenquelle(n) BASEC: Import vom 23.05.2025 ICTRP: N/A
  • Letzte Aktualisierung 23.05.2025 10:56

Zusammenfassung der Studie

The objective of this study is to confirm the safety and performance of the Hexanium TLIF system from SPINEVISION in patients with degenerative disc disease. This observational study will collect data on the occurrence of adverse events, as well as the evolution of pain and functional disability, over a period of two years after lumbar fusion surgery with the Hexanium TLIF cage from SPINEVISION.

(BASEC)

Untersuchte Intervention

The surgical technique of "transforaminal lumbar intervertebral fusion" involves the implantation of a medical device (called a cage, here the Hexanium TLIF - SPINEVISION) in place of the defective intervertebral disc, which has been previously removed (partially or entirely); this is done to stabilize one to two segments at the level of the lumbar spine.

(BASEC)

Untersuchte Krankheit(en)

Degenerative disc disease is a natural degradation of an intervertebral disc in the spine. This degradation is often the result of natural daily stresses and minor injuries. Degenerative disc disease is typically treated with exercises, medications (pain relievers), and physical therapy. When these standard treatments prove ineffective, lumbar fusion surgery is considered.

(BASEC)

Kriterien zur Teilnahme
1. Patient implanted with / scheduled for implantation with the Hexanium TLIF device: • Patient already implanted with the Hexanium TLIF (implantation date not earlier than July 2021), or • Patient scheduled for implantation with the Hexanium TLIF implant; 2. Patient aged 18 years or older; 3. Patient who has given signed consent or has not opposed the collection of their data, according to local regulations. (BASEC)

Ausschlusskriterien
The contraindications are as follows: - a local infection at the surgical site; - signs of local inflammation; - fever or leukocytosis; - morbid obesity; - pregnancy; - pediatric cases or patients whose skeleton is still undergoing general growth; - cases of spondylolisthesis (vertebral slippage) where reduction to grade I is impossible; - a proven or suspected allergy or intolerance to metals; - any case where the selected components for implantation are too large or too small to achieve the desired outcome; - any patient whose tissue coverage of the surgical site is inadequate, or whose bone quality or capital is poor; - any patient for whom the use of an implant would compromise the anatomical structures or expected physiological performance; - a previous arthrodesis at the level to be treated; an arthrodesis is a surgical procedure that involves fusing two or more vertebrae together to treat a back problem; - any case that does not require a bone graft or an arthrodesis; - any presence of an anomaly compromising the normal process of bone remodeling including, but not limited to: severe osteoporosis involving the spine, bone resorption, osteopenia, primary or metastatic tumors involving the spine, active infection at the site or proven metabolic disorders compromising osteogenesis; - mental disorders; - any patient unwilling to comply with post-operative instructions. (BASEC)

Studienstandort

Genf

(BASEC)

nicht verfügbar

Sponsor

SPINEVISION SAS Easy Medical Device

(BASEC)

Kontakt für weitere Auskünfte zur Studie

Kontaktperson Schweiz

RANAIVOSON Hanta

+33 1 53 33 25 25

clinical.study@spinevision.com

SPINEVISION SAS

(BASEC)

Wissenschaftliche Auskünfte

nicht verfügbar

Name der bewilligenden Ethikkommission (bei multizentrischen Studien nur die Leitkommission)

Ethikkommission Genf

(BASEC)

Datum der Bewilligung durch die Ethikkommission

21.11.2023

(BASEC)


ICTRP Studien-ID
nicht verfügbar

Offizieller Titel (Genehmigt von der Ethikkommission)
Safety and Performance of the Hexanium® TLIF system in the treatment of skeletally mature patients suffering from degenerative disc disease (BASEC)

Wissenschaftlicher Titel
nicht verfügbar

Öffentlicher Titel
nicht verfügbar

Untersuchte Krankheit(en)
nicht verfügbar

Untersuchte Intervention
nicht verfügbar

Studientyp
nicht verfügbar

Studiendesign
nicht verfügbar

Ein-/Ausschlusskriterien
nicht verfügbar

nicht verfügbar

Primäre und sekundäre Endpunkte
nicht verfügbar

nicht verfügbar

Registrierungsdatum
nicht verfügbar

Einschluss des ersten Teilnehmers
nicht verfügbar

Sekundäre Sponsoren
nicht verfügbar

Weitere Kontakte
nicht verfügbar

Sekundäre IDs
nicht verfügbar

Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten
nicht verfügbar

Weitere Informationen zur Studie
nicht verfügbar

Ergebnisse der Studie

Zusammenfassung der Ergebnisse

nicht verfügbar

Link zu den Ergebnissen im Primärregister

nicht verfügbar